number of access : ?
number of downloads : ?
ID 115274
Author
Takehisa, Yozo Hakuai Memorial Hospital
Bando, Hiroshi Hakuai Memorial Hospital|Tokushima University KAKEN Search Researchers
Keywords
Dulaglutide
Glucagon-like Peptide-1 Receptor Analogue
Type 2 Diabetes Mellitus
Oral Hypoglycemic Agents
Heisei Medical Welfare
Content Type
Journal Article
Description
Background: For diabetic treatment, Dulaglutide has been used and effective as a glucagon-like peptide-1 receptor analogue (GLP-1 RA). This report is to describe the various responses and to analyze dulaglutide administration in the elderly with DM. Case presentation: Two patients were Type 2 Diabetes Mellitus (T2DM) treated with add-on therapy of Dulaglutide. Case 1 is 81-year-old female is diabetic for 2 years, and on Metformin and Glimepiride as Oral Hypoglycemic Agents (OHAs). Her HbA1c was higher with 10.6% and she was started to given Dulaglutide 0.75mg. Remarkable efficacy was found in 3 months with HbA1c 6.7%. Value of LDL-C increased from 135 mg/dL to 158 mg/dL. Case 2 is 83-year-old male with 27 years of diabetes. He was on medication of Metformin and Glimepiride. His HbA1c persisted around 9.0%-9.4%, then he was provided Dulaglutide as add-on therapy. In 3 months, HbA1c decreased to 8.2% and LDL-C increased from 57 mg/dL to 116 mg/dL. Discussion and conclusion: Dulaglutide is a useful GLP-1 RA with once a week administration. There were some reports concerning LDL changes after dulaglutide therapy, showing that the changes may depend on the basal LDL value before the administration of dulaglutide. Dulaglutide may influence lipid metabolism. This report is expected to become reference in diabetic practice and research in the future.
Journal Title
Edelweiss Journal of Biomedical Research and Review
ISSN
26902613
Publisher
Edelweiss Publications
Volume
2
Issue
1
Start Page
31
End Page
35
Published Date
2020-09-10
Rights
© 2020 Takehisa Y, et al., This is an open-access article distributed under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences